# Semax FAQ: Side Effects, Legality, Hormones, and the Research Record > Frequently asked questions about Semax — side effects in the published trials, legal status in the US and Russia, hormone effects, storage, stimulant classification, and stacking. ## Reported Side Effects in the Semax Literature Semax side effects in the published Russian clinical record are described as mild and infrequent at the doses studied. The 10-day intranasal stroke-recovery course in Gusev 1997 reported no major adverse-event signal versus the conventional-therapy arm [7]. The six-month cerebrovascular insufficiency study by Kaplan 2005 likewise reported no major safety signals beyond the trial's powering [22]. The most commonly noted minor effects across the broader Russian literature are nasal irritation from the intranasal route, transient mild headache, and occasional sleep-pattern shifts during multi-day courses — none of these were quantified in detail in the indexed trial summaries. Long-term safety data beyond the published clinical course windows is limited. The peptide's short plasma half-life and the absence of corticotropic activity in the ACTH 4-10 fragment reduce some of the concerns that would attach to the parent ACTH hormone, but absence of evidence is not evidence of absence. ## Who is excluded from Semax research? Published trial protocols exclude pregnancy, severe psychiatric instability, and uncontrolled hypertension — described as research-protocol exclusions, not personal medical guidance. These exclusions are standard for CNS-active peptide trials and reflect protocol caution rather than documented adverse signals in the excluded populations. ## Does Semax affect hormones? Despite the ACTH 4-10 lineage, the 4-10 fragment was specifically chosen because it lacks the corticotropic activity of full ACTH [1][2]. Published data show no clinically meaningful HPA-axis activation at studied doses. The Pro-Gly-Pro tail extends stability without restoring corticotropic function. The hormonal footprint is small — the peptide engages melanocortin receptors and the neurotrophic and monoaminergic systems, not the cortisol axis. ## Legal status of Semax internationally Semax is approved as a prescription medication in Russia and has been on Russia's List of Vital and Essential Drugs since 2011. It is sold internationally as a research chemical with varying regional rules. It is not approved by the EMA, the FDA, the MHRA, or any other Western regulator for any indication. Regional research-chemical sale framing applies. ## Semax legal status in the United States Semax is not FDA-approved for any indication in the United States. It is sold in the US only as a research chemical, with the standard 'not for human use' framing applied to that category. It is not a scheduled substance under the Controlled Substances Act. International peptides ordered into the US for personal use may be subject to FDA import action; the regulatory situation is fluid and is not legal advice. ## Is Semax a stimulant? No — Semax acts via neurotrophic and serotonergic mechanisms rather than catecholamine release [3][6]. The published literature classifies it as a nootropic and neuroprotective peptide, not a CNS stimulant. The cognitive signal is downstream of BDNF and NGF expression on a timescale of hours to days, not the minutes-scale dopamine release characteristic of amphetamines. Acute monoaminergic activation does occur — striatal 5-HIAA rises within hours — but the magnitude and pharmacology differ from classical stimulant action. ## Semax storage stability Lyophilized Semax is stable at room temperature short-term per general research-peptide handling guidance. Reconstituted Semax is typically stored refrigerated to preserve peptide integrity, with use within the window specified by the study or supplier. The Pro-Gly-Pro C-terminal tail confers proteolytic stability versus the bare ACTH 4-10 fragment, but the reconstituted solution is still a peptide and behaves like one. --- A chalkboard reading of fifty years of Russian neurochemistry on one heptapeptide — lecture notes from the literature, not a clinic, not a vendor, not a prescription.